Suchergebnisse - "O'Day, Steven J"

PubPharm (58)

1

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma : results from the CAPRA study

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Silk, A. | O'Day, S. | Kaufman, H. | +19

2

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Rudin, C. | Pandha, H. | Zibelman, M. | +18

3

Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19

enthalten in: Science translational medicine | 2021

von D'Agnillo, F. | Walters, K. | Xiao, Y. | +25

4

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical Trials

enthalten in: JAMA oncology | 2020

von Puzanov, I. | Ribas, A. | Robert, C. | +18

5

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

enthalten in: Journal for immunotherapy of cancer | 2020

von Arnaldez, F. | O'Day, S. | Drake, C. | +8

6

Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy

enthalten in: Clinical chemistry | 2020

von Lin, S. | Chang, S. | Lam, S. | +11

7

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States : An Expanded Access Program

enthalten in: Journal of immunotherapy (Hagerstown, Md. : 1997) | 2017

von Gangadhar, T. | Hwu, W. | Postow, M. | +14

8

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

enthalten in: Journal for immunotherapy of cancer | 2016

von Amin, A. | Lawson, D. | Salama, A. | +8

9

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2015

von Ribas, A. | Puzanov, I. | Dummer, R. | +33

CommentIn: Lancet Oncol. 2015 Aug;16(8):873-4. - PMID 26115798

10

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Carvajal, R. | Lawrence, D. | Weber, J. | +17

1
2
3
4
5
6
Nächster »
[6]